SCHEMBL3533259

SCHEMBL3533259

CC1CCN(c2nc(N3CCN(C)CC3)cnc2[N+](=O)[O-])CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
HRH4 Q9H3N8 4/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HTR3A P46098 1/20 0.40
ALDH1A1 P00352 4/20 0.40
POLB P06746 2/20 0.40
CSF1R P07333 1/20 0.40
MAPK1 P28482 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
OGA O60502 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
MET P08581 1/20 0.37
CTSB P07858 1/20 0.37
TDP1 Q9NUW8 1/20 0.36
SIRT6 Q8N6T7 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
GPR174 Q9BXC1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3539291 0.79 MAPT (0.63) MAPTMEN1KMT2AALDH1A1POLB
SCHEMBL3538803 0.78 ROCK2 (0.46) HRH4HTR3ACSF1ROGAHRH3
SCHEMBL3537307 0.77 HRH4 (0.47) CYP2D6CYP2C9HRH4KMT2AHTR3A
SCHEMBL3541566 0.76 MAPT (0.46) MAPTCYP2D6CYP2C9HRH4MEN1
SCHEMBL13405746 0.76 ALDH1A1 (0.48) MAPTCYP2D6CYP2C9MEN1KMT2A
SCHEMBL3535973 0.69 HTR3A (0.49) HRH4MEN1KMT2AHTR3AALDH1A1
SCHEMBL609738 0.67 SIRT6 (0.45) MAPTCYP2D6CYP2C9HRH4MEN1
SCHEMBL3535724 0.67 MAPT (0.49) MAPTMEN1KMT2AALDH1A1POLB
SCHEMBL3537264 0.67 MAPT (0.54) MAPTMEN1KMT2AALDH1A1POLB
SCHEMBL3537856 0.67 MAPT (0.48) MAPTMEN1KMT2AALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES MAPT 159/4885CYP2D6 3105/4885CYP2C9 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.